Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD)
A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of Oral FXR Modulator EYP001a Combined With Nucleos(t)Ide Analogues (NA) in Virologically Suppressed Chronic Hepatitis B Patients to Improve Functional Cure Rates
Sponsor: Enyo Pharma
Terminated
DSMC reviewed results of 26 subjects. New randomizations were stopped. Already randomized subjects were followed up to W40.
Other terminated trials from Enyo Pharma
Listed as NCT04465916, this PHASE2 trial focuses on Hepatitis B, Chronic and remains terminated or withdrawn. Sponsored by Enyo Pharma, it has been updated 9 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Nov 2022 — Dec 2022 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
▶ Show 4 earlier versions
-
Jun 2021 — Nov 2022 [monthly]
Active Not Recruiting PHASE2
-
May 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE2
First recorded
May 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Enyo Pharma
- Eurofins
- Novotech (Australia) Pty Limited
- Parexel
- Synteract, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bialystok, Poland , Brisbane, Australia , Hong Kong, Hong Kong , Kielce, Poland , Lodz, Poland , Lublin, Poland , Melbourne, Australia , Pusan, South Korea , Seongnam, South Korea , Seoul, South Korea and 2 more locations